RifaximinThird Party Manufacturing in India

Rifaximin is a semisynthetic rifamycin antibiotic that exerts its antimicrobial effects by binding to the beta subunit of bacterial DNA-dependent RNA polymerase, thereby inhibiting bacterial RNA synthesis. This mechanism is shared with other rifamycins, but rifaximin is structurally modified with a pyridoimidazole ring that renders the molecule poorly absorbable from the gastrointestinal tract, with less than 0.4 percent oral bioavailability. This non-systemic property allows rifaximin to achieve high intraluminal concentrations in the gut while minimizing systemic exposure and associated toxicity. The drug has a broad spectrum of activity against both Gram-positive and Gram-negative aerobic and anaerobic enteric bacteria, including Escherichia coli, Salmonella species, Shigella species, Campylobacter jejuni, and Clostridium difficile. Rifaximin also reduces bacterial virulence factor expression and adherence to intestinal epithelial cells. Beyond its direct antibacterial effects, rifaximin modulates the gut microbiome composition and exerts anti-inflammatory effects through activation of the pregnane X receptor, which downregulates pro-inflammatory cytokine production in intestinal epithelial cells. This combination of antibacterial, microbiome-modulating, and anti-inflammatory activities underlies its efficacy in a range of gastrointestinal disorders. The molecule is zwitterionic, with pH-dependent solubility that is minimal in the acidic gastric environment but increases significantly in the neutral to alkaline pH of the small and large intestine, targeting drug release to the lower gastrointestinal tract where its therapeutic effects are needed.

Therapeutic Uses

Rifaximin is prescribed for the treatment of:

• Travelers Diarrhea: For the treatment of uncomplicated travelers diarrhea caused by non-invasive strains of Escherichia coli in adults and children twelve years of age and older.
• Irritable Bowel Syndrome with Diarrhea (IBS-D): For the reduction of global IBS symptoms and improvement of stool consistency in adult patients with IBS-D, typically given as a fourteen-day course.
• Hepatic Encephalopathy: For the reduction of risk of overt hepatic encephalopathy recurrence in patients with advanced liver disease, through reduction of ammonia-producing gut bacteria.
• Small Intestinal Bacterial Overgrowth (SIBO): For the treatment of SIBO, where rifaximin eradicates excess bacteria in the small intestine and improves associated symptoms of bloating, diarrhea, and malabsorption.
• Diverticulitis: As adjunctive therapy for the prevention of recurrent diverticulitis and for the management of uncomplicated diverticular disease.

Why Manufacturers Choose Rifaximin

Rifaximin is a high-value antibiotic molecule that commands premium pricing due to its unique non-systemic mechanism and patented applications in multiple gastrointestinal indications. The molecule is available in tablet strengths of 400mg and 550mg BP, with the 550mg strength being the FDA-approved dose for IBS-D and hepatic encephalopathy. The Indian market for rifaximin has grown substantially with increasing awareness of SIBO and the expanding use of rifaximin in gastroenterology practice. For third party manufacturers, rifaximin represents a differentiated product opportunity in the antibiotic segment, with strong prescription demand from gastroenterologists and general practitioners. The molecule requires WHO-GMP certified facilities with expertise in film coating technology. Export opportunities are particularly strong for Indian manufacturers targeting regulated markets including the United States and Europe, as well as emerging markets in Asia and Africa where gastrointestinal infectious diseases remain prevalent. The well-established safety profile, lack of systemic side effects, and low potential for drug interactions make rifaximin an attractive molecule for PCD franchise distribution.

This makes Rifaximin one of the most sought-after antibiotics for third party manufacturing in India, with growing demand from PCD franchise operators and export-oriented pharmaceutical companies.